Inovalon Holdings Inc (INOV) reported quarterly earnings results on Wednesday, May-4-2016. The company reported $0.05 earnings per share for the quarter, missing the analyst consensus estimate by $-0.03. Analysts had a consensus of $0.08. The company posted revenue of $102.70 million in the period, compared to analysts expectations of $97.96 million. The company’s revenue was up 9.7% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.11 EPS.
Many Wall Street Analysts have commented on Inovalon Holdings Inc. Shares were Downgraded by Robert W. Baird on Apr 21, 2016 to ” Neutral” and Lowered the Price Target to $ 21 from a previous price target of $22 .Inovalon Holdings Inc was Downgraded by Morgan Stanley to ” Underweight” on Mar 30, 2016. KeyBanc Capital Mkts Initiated Inovalon Holdings Inc on Mar 29, 2016 to “Overweight”, Price Target of the shares are set at $26.
Inovalon Holdings Inc closed down -0.1 points or -0.58% at $17 with 3,84,945 shares getting traded on Monday. Post opening the session at $17.15, the shares hit an intraday low of $16.97 and an intraday high of $17.46 and the price fluctuated in this range throughout the day.Shares ended Monday session in Red.
In a different news, on Mar 7, 2016, Robert A Wychulis (President) sold 33,003 shares at $18.17 per share price. According to the SEC, on Dec 10, 2015, Daniel L Rizzo (Chief Innovation Officer) sold 24,000 shares at $20.00 per share price. On Dec 7, 2015, Shauna L Vernal (Chief Legal Officer) sold 33,437 shares at $18.55 per share price, according to the Form-4 filing with the securities and exchange commission.
Inovalon Holdings Inc. is a technology company. The Company combines advanced cloud-based data analytics and data-driven intervention platforms to provide services for health plans hospitals physicians patients pharmaceutical companies and researchers. Through its datasets integration technologies predictive analytics and subject matter expertise the Company delivers platforms. Its analytics identify gaps in care quality data integrity and financial performance while providing clients with capabilities to resolve these gaps. The Company’s data analytics and intervention platforms consist of four primary components: data integration advanced analytics intervention platforms and business processing. This system manages the process of defining and configuring industry data feeds from its clients and partners including electronic health records laboratory pharmacy patient reported claims paper based medical records biometric and hospital data feeds.